Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Karger Publishers 2023-05-01
Schriftenreihe:	Liver Cancer
Schlagworte:	hepatocellular carcinoma thyroid adverse events atezolizumab bevacizumab
Online-Zugang:	https://beta.karger.com/Article/FullText/531182
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!